Sai Parenteral's Limited IPO: Issue Price, Listing Gain and Share Price Now
Sai Parenteral's Limited listed on 02-Apr-2026 at ₹406.4 against an issue price of ₹392 , a listing gain of +3.67%. It last traded at ₹528.75 (25-Aug-2026). This page is the record of that issue and what has happened to it since — reported figures only.
Sai Parenteral's Limited IPO: listing gain and return since
| Measure | Value |
|---|---|
| Issue price | ₹392 |
| Listing price (listing-day close) | ₹406.4 |
| Listing gain | +3.67% |
| Price now | ₹528.75 |
| Change from issue price | +34.89% |
| Change from listing-day close | +30.11% |
The two changes above answer different questions and are routinely opposite in sign. The change from the issue price is what an allottee has made. The change from the listing-day close is what somebody who bought on the first day has made.
Sai Parenteral's Limited IPO details
| Issue term | Detail |
|---|---|
| Issue price (upper band) | ₹392 |
| Issue size | ₹408.79 Cr |
| Fresh issue | ₹285 Cr |
| Offer for sale | ₹123.79 Cr |
| Issue opened | 24-Mar-2026 |
| Issue closed | 27-Mar-2026 |
| Listed on | 02-Apr-2026 |
| Exchange | BSE, NSE |
| Segment | Mainboard |
| Lead managers | Arihant Capital (left lead) |
How the Sai Parenteral's Limited IPO was subscribed
| Category | Subscription |
|---|---|
| QIB | 1.73x |
| NII | 2.45x |
| Retail | 0.12x |
| Total | 1.08x |
Sai Parenteral's Limited today
| Figure | Value |
|---|---|
| Market capitalisation | ₹2,401 Cr |
| Trailing P/E | 116.00x |
| Return on capital employed | 6.0% |
| Return on equity | 4.9% |
| 52-week high | ₹706 |
| 52-week low | ₹400 |
| Sector | Pharmaceuticals |
Fundamentals are as of the desk's last harvest and move with the market.
- Sai Parenteral's Limited — full issue page: every stored figure, with its source.
- How many IPOs still trade above their issue price, corporate-action adjusted.
- The full IPO archive: listing gains by year, sector and issue size.
Automated data digest. This page is compiled automatically from exchange filings and public aggregator data. It is a record of reported figures — it is not research, not a recommendation, and not investment advice.
Grey Market Premium (GMP) is an unofficial, unregulated price quoted outside the exchanges. It is not a forecast of the listing price and is frequently wrong.
Published by INVESTOLOGY — SEBI Registered Research Analyst INH000015297. Investments in securities markets are subject to market risk; read all offer documents carefully before investing. Registration granted by SEBI and NISM certification in no way guarantee performance or assure returns.